In Vitro Functional Modulation of Monocyte-derived Dendritic Cells of Patients With Cancer by Peptides

Overview

The purpose of this study is to evaluate in vitro the potential of peptides, to modify, phenotypically and functionally, the monocyte-derived dendritic cells of patients with metastatic cancer.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2014

Detailed Description

The DCs will be generated in vitro from peripheral blood mononuclear cells (PBMCs) which will be obtained from 30 ml of peripheral blood collected from each patient with metastatic cancer by venipuncture in heparin tubes. The cellular viability, the expression of maturation biomarkers and the presence of several cytokines will be evaluated by flow cytometric assays after the culture period of DCs exposed to the peptides. An interim analysis is programmed with the first 10 patients. If an effect is demonstrated the study will include an additional number of subjects sufficient to ensure adequate comparison with other commercially available peptides.

Interventions

  • Other: Blood sampling by vena punction.
    • In vitro tests will be performed after blood sample collection from metastatic cancer patients

Arms, Groups and Cohorts

  • Patients with metastatic cancer
    • Blood sampling by vena punction.

Clinical Trial Outcome Measures

Primary Measures

  • Expression of cellular markers in the dendritic cells (DCs) after stimulation with the peptides.
    • Time Frame: At the seventh day of the cells culture period
  • Viability of the dendritic cells (DCs) after stimulation with the peptides.
    • Time Frame: At the seventh day of the cells culture period
  • Cytokines production by the dendritic cells (DCs) after stimulation with the peptides.
    • Time Frame: At the seventh day of the cells culture period

Participating in This Clinical Trial

Inclusion Criteria

1. Signature of the Informed Consent Form before the performing of any procedures related to the study; 2. Age ≥18 years; 3. Histologically confirmed metastatic malignant neoplasia; 4. Results of laboratorial exams in the first 6 weeks before the blood sample collection within the following values:

  • White blood cells ≥ 3.000/μL; – Platelet count ≥ 100,000/mm³; – Hemoglobin > 10g/dL; – Serum aspartate aminotransaminase (AST), alanine aminotransferase (ALT) and alkaline phosphatase < 2.5 x upper limit of normal (ULN); – Serum creatinine < 1.5 x upper limit of normal (ULN); 5. Karnofsky performance status ≥ 70%. Exclusion Criteria:

1. Presence of autoimmune disorders or conditions that require systemic treatment with immunosuppressant medications or systemic corticosteroids; 2. Received any systemic chemotherapy or radiotherapy within 15 days prior to the blood sample collection; 3. Received any immunotherapy within 4 weeks prior to the blood sample collection; 4. Known history of positive serology for HIV (human immunodeficiency virus).

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Recepta Biopharma
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • José AM Barbuto, Ph.D, Study Chair, Departamento de Imunologia – Instituto de Ciências Biomédicas da Universidade de São Paulo

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.